Proton Therapy Lowers Risk of Side-Effects Compared to Conventional Radiation
In largest study of its kind, Penn researchers compare overall adverse events of proton and photon therapies
Newswise — PHILADELPHIA – Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of experiencing side-effects from their radiation therapy, while cure rates are almost identical between the two groups. Researchers in the Perelman School of Medicine at the University of Pennsylvania conducted the largest review of its kind to evaluate whether or not patients undergoing radiation therapy at the same time as chemotherapy experienced serious adverse events within 90 days. They will present their findings at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago (Abstract #6521).
“We looked at grade-three side effects – including pain or difficulty swallowing, difficulty breathing, nausea, or diarrhea, among others – often severe enough for patients to be hospitalized,” said the study’s lead author Brian Baumann, MD, an adjunct assistant professor of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania and an assistant professor of Radiation Oncology at Washington University School of Medicine in St. Louis. “Our clinical experience is that concurrent chemoradiation therapy patients treated with protons, rather than photons, tend to have fewer side effects. While there is some literature supporting that finding for several disease sites, we did not expect the magnitude of the benefit to be this large.”
Proton therapy has a few key differences from traditional photon radiation. Photon radiation typically uses multiple x-ray beams to attack a tumor target but unavoidably deposits radiation in the normal tissues beyond the target, potentially damaging those tissues as the beam exits the body. Proton therapy is an FDA-approved treatment that is an alternative radiation treatment. It directs positively charged protons at the tumor target, where they deposit the bulk of the radiation dose, with minimal residual radiation delivered beyond the target, potentially reducing side effects and damage to surrounding tissue.
For this study, researchers evaluated data on 1,483 cancer patients, 391 of whom received proton therapy and 1,092 who underwent photon treatment. All patients had non-metastatic cancer and were undergoing chemotherapy and radiation intended to be curative. Patients with brain cancer, head and neck cancer, lung cancer, gastrointestinal cancer, and gynecologic cancer treated with concurrent chemoradiation were included. The primary outcome was whether or not patients experienced radiation side-effects that were grade-three or higher within 90 days of treatment.
Data showed 11.5 percent (45) of proton patients experienced a grade three or higher side-effect. In the photon group, 27.6 percent (301) experienced a grade three or higher side-effect. A weighted analysis of both patient groups, which controlled for other factors that may have led to differences between the patient groups, found that the relative risk of a severe toxicity was two-thirds lower for proton patients compared to photon patients.
Importantly, overall survival and disease-free survival were similar between the two groups, suggesting that the reduction in toxicity seen with proton therapy did not come at the cost effectiveness. While researchers say more study is needed, they point out that this study is the best information we have so far as randomized controlled trials continue to prove difficult to complete.
“There are several trials underway, but they are all dealing with a variety of barriers, so it will be years before we have that data. That’s why the information we do have is so critical, and our findings here point to a real benefit for our patients,” Metz said.
Baumann will present the findings as a poster session on Saturday, June 1st, at 1:15 p.m. central in McCormick Place Hall A.
Editor’s Note: Metz has served on proton therapy advisory boards for Varian Medical Systems and IBA, neither of which funded or had any role in this research.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.